News & Events

Press Releases

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Events

H.C. Wainwright Global Investment Conference

May 24 - May 27

Q1 2022 Salarius Pharmaceuticals Earnings Webcast and Conference Call

May 12 @ 5:00pm EST

Listen to Webcast

Q4 2021 Salarius Pharmaceuticals Earnings Webcast and Conference Call

Mar 10 @ 5:00pm EST

Listen to Webcast

Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference

Feb 24

In the News

Global Newswire

Salarius Expands Oncology Pipeline Through Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

The Clinical Trials Guru

David Arthur, Salarius CEO Speaks with Dan Sfera of The Clinical Trials Guru

Houston Business Journal

Salarius Pharmaceuticals raises millions for expanded clinical trial, moves office in TMC

15 Biotech Companies in Houston Making a Major Impact on Medicine

Empowered Patient Podcast

Targeting Epigenetic Causes of Ewing’s Sarcoma with David Arthur Salarius Pharmaceuticals on Empowered Patient Podcast with Karen Jagoda

Reportable News

Salarius During the JP Morgan Week – Attend the Biotech Showcase Presentation or Join the Live Webcast